Objective:This study sought to evaluate the long-term safety and efficacy of the Firebird sirolimus-eluting stent in patients with multi-vessel coronary artery disease.The main limitation of percutaneous coronary intervention(PCI)with bare metal stents(BMS)was the increased incidence of instent restenosis.Recently,DES are frequently implanted in patients with off-label indications such as multi-vessel coronary artery disease.However,the long-term safety and effectiveness of DES among patients with multi-vessel coronary artery disease are not well understood.Methods:From January to December 2006,a total of 392 patients with multi-vessel coronary artery disease,exclusively treated with Firedird stents at 12 centers from China,were enrolled in this prospective,multicenter registry.They were followed up clinically at 6,12,18 and 24 months after the procedure.Results:A core laboratory analyzed quantitative coronary angiography data immediately after stenting and at 6-month follow-up.Acute angiographic success was 100%.Angiographic restenosis rate was 2.80% at the sixth month.The percentage of acute major adverse cardiac events(MACE)was 4.86%,4.37% and 6.91%,and the percentage of secondary cardiac events was 5.62%,5.88% and 6.39% at 12,18 and 24 months,respectively.The incidence of death,myocardial infarction,or stent thrombosis during 24 month was 3.84%(15 of 392),1.02%(4 of 392)or 2.05%(8 of 392).Conclusion:This study indicates that Firebird sirolimus-eluting stent is safe and effective for patients with multi-vessel coronary artery disease.
